Effectiveness of Personalized Surveillance and Aftercare for Breast Cancer

Enrolling by invitationOBSERVATIONAL
Enrollment

1,040

Participants

Timeline

Start Date

March 6, 2023

Primary Completion Date

March 6, 2027

Study Completion Date

March 6, 2027

Conditions
Breast CancerBreast Cancer FemaleSurvivorship
Interventions
OTHER

personalized surveillance plans (PSP) and personalized aftercare plans (PAP)

The PSP contains decisions on the surveillance trajectory based on individual risks and needs, assessed with the 'Breast Cancer Surveillance Decision Aid' including the INFLUENCE prediction tool. The PAP contains decisions on the aftercare trajectory based on individual needs and preferences and available care resources, which decision-making is supported by a patient decision aid.

Trial Locations (10)

Unknown

Gelre Ziekenhuizen, Apeldoorn

Rijnstate, Arnhem

Jeroen Bosch Ziekenhuis, 's-Hertogenbosch

Bernhoven Ziekenhuis, Uden

Noordwest Ziekenhuisgroep, Alkmaar

Ziekenhuisgroep Twente, Hengelo

Isala Klinieken, Zwolle

Albert Schweitzer Ziekenhuis, Dordrecht

Alrijne Ziekenhuis, Leiderdorp

Haaglanden Medisch Centrum, The Hague

All Listed Sponsors
collaborator

University of Twente

OTHER

collaborator

Dutch Breast Cancer Association

UNKNOWN

collaborator

Borstkanker Onderzoek Groep

NETWORK

collaborator

Netherlands Institute for Health Services Research

UNKNOWN

lead

Comprehensive Cancer Centre The Netherlands

OTHER